Trial Profile
A Study in Healthy Subjects to Assess the Multiple-Dose Pharmacokinetics of Two AF-219 Formulations
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs Gefapixant (Primary) ; Omeprazole (Primary)
- Indications Asthma; Cough; Interstitial cystitis; Musculoskeletal pain
- Focus Pharmacokinetics
- Sponsors Afferent Pharmaceuticals
- 16 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 22 Jul 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 13 Jul 2015 New trial record